Combined homologous recombination repair deficiency and immune activation analysis for predicting intensified responses of anthracycline, cyclophosphamide and taxane chemotherapy in triple-negative breast cancer

BACKGROUND: Triple-negative breast cancer (TNBC) is a clinically aggressive disease with abundant variants that cause homologous recombination repair deficiency (HRD). Whether TNBC patients with HRD are sensitive to anthracycline, cyclophosphamide and taxane (ACT), and whether the combination of HRD...

Descripción completa

Detalles Bibliográficos
Autores principales: Liao, Gaoming, Jiang, Zedong, Yang, Yiran, Zhang, Cong, Jiang, Meiting, Zhu, Jiali, Xu, Liwen, Xie, Aimin, Yan, Min, Zhang, Yunpeng, Xiao, Yun, Li, Xia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8408988/
https://www.ncbi.nlm.nih.gov/pubmed/34465315
http://dx.doi.org/10.1186/s12916-021-02068-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8408988/
https://www.ncbi.nlm.nih.gov/pubmed/34465315
http://dx.doi.org/10.1186/s12916-021-02068-4

Ejemplares similares